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Abstract 
 
In high-risk women, risk reducing surgery remains the cornerstone of 
prevention. However, the resulting premature menopause has led to continued 
efforts to develop effective screening strategies for those who wish to delay or 
avoid surgery. This review describes how the screening of women at risk of 
ovarian and endometrial cancer has evolved to its current state. Serial 
monitoring of CA125 is core to ovarian cancer screening and most recent studies 
have used the Risk of Ovarian Cancer Algorithm (ROCA) to interpret CA125 
profile. The additional use of a second tumour marker, HE4, is reviewed. The 
results to date of key ovarian cancer screening studies in high-risk women are 
summarised ahead of their concluding findings due later in 2016.  The role of 
both ultrasound and endometrial sampling in the management of women at 
increased risk of endometrial cancer is outlined.  Exciting new methodology, 
which could help shape the future of screening is investigated. The article 
summarises the current recommendations and guidelines from recognised 
international bodies to aid the clinician with management of these women.  
 
 
 
Key words 
Screening, BRCA, Ovarian, Endometrial, CA125, Transvaginal, ultrasound, Lynch,  
 
 
 
 
 4 
 
Increasing availability of genetic testing and falling costs of the tests suggests 
that growing numbers of unaffected women will be identified worldwide who 
are at increased  risk of gynaecological malignancies. The challenge in those 
identified is to prevent and detect the disease early without causing significant 
harm. Currently surgery remains the cornerstone of management. Most women 
undergoing surgery do not report a significant deterioration of their physical and 
mental health-related quality of life (1). However the resulting premature 
menopause is associated with decrease in sexual functioning and vasomotor 
symptoms even in women on hormone replacement therapy (HRT)(2)(3). As a 
result there is a continued effort to develop effective screening strategies for 
high risk women. 
 
Ovarian cancer screening 
 
Women at high risk of ovarian cancer are in the main BRCA mutation carriers 
with a 11- 68 % lifetime risk of ovarian/tubal cancer (4)(5). Women with Lynch 
Syndrome can have a risk of ovarian cancer of up to 24%. (6). Testing is also 
increasingly be available for moderate penetrance mutations in genes such as 
RAD51C, RAD51D, BRIP1 where lifetime risks of ovarian cancer are in the range 
of 5-15%.(7)(8) Finally, the multiple common low-penetrance susceptibility 
alleles which individually confer relative risks of less than 1.5-fold (7) in 
combination with lifestyle and reproductive factors are likely to identify 
additional women with an increased lifetime ovarian cancer. (9)(10). Significant 
efforts are underway to incorporate recently identified moderate and low risk 
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loci as well as lifestyle and reproductive factors to models such as the BOADICEA 
in order to personalise risk prediction(11).(12).   
 
Risk reducing salpingo-oophrectomy (RRSO) after the age of 35 and completion 
of the family is the primary recommendation in  BRCA1/2 carriers and has been 
proven to substantially reduce the risk of developing ovarian/tubal cancer (13) 
(14). In those unwilling to explore surgery, screening is an option.  The currently 
available strategies are based on blood tests for tumour markers and adnexal 
imaging, in particular using transvaginal ultrasound (TVS). 
   
Bimanual pelvic examination, although widely used in clinical practice, lacks 
sensitivity and specificity for both the detection of ovarian cancer and the ability 
to distinguish benign from malignant lesions. A systematic review  of  screening 
populations that were both asymptomatic and symptomatic  and included high 
risk women found the positive predictive value of an abnormal pelvic 
examination is only 1% (95% CI=0.67%, 3.0%). (15) (16). Despite this, in a 
recent survey of US obstetricians and gynaecologists, 47% stated that they 
performed pelvic examinations for early detection of ovarian cancer (17). 
 
The potential role of ultrasound in ovarian cancer screening was initially 
explored alongside CA125 in the 1980s (18)(19). Since then, there have been key 
improvements aimed at increasing the sensitivity as well specificity and positive 
predictive value of ultrasound screening which include transvaginal rather than 
transabdominal ultrasound, the introduction of  colour Doppler to monitor 
neovascularisation (20) and use of morphological index (MI) based upon 
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ultrasound features of the lesion (21) and finally change in serial MI scores as the 
mean MI for malignant ovarian tumors increases over time, while that of non-
malignant tumors decrease or remain stable (22) As ultrasound revealed the 
natural behavior of cysts and the high incidence of spontaneous regression of 
benign / functional cysts  (23) repeat scanning to confirm persisitence in 4-6 
weeks became the norm in ultrasound scanning.  
 
The main blood tumour marker is serum CA125, which was first described by 
Bast in 1981. It is a 200kd glycoprotein recognised by the OC125 murine 
monoclonal antibody (24). There are a number of CA125 assays available, most 
of which correlate well with each other and are clinically reliable. The results are 
often interpreted using a cut-off value based upon the 99% centile of normal 
distribution which in pre menopausal women is 35 U/mL.  (25). However CA125 
values can show wide variation, being influenced by race, age, menstrual cycle, 
pregnancy, a range of benign gynaecological conditions and inflammatory 
conditions such as pancreatitis and pleuritis. Elevated levels are found in 
approximately 85% of women with epithelial cancer (26)(27), with  raised levels 
in the preclinical asymptomatic phase being described as early as 1988. (26). 
   
It has become increasingly clear that in ovarian cancer screening, a key issue is 
how tumour marker levels are interpreted.  When interpreting CA125, which is 
not cancer specific, a single threshold rule is not effective. In screening trials in 
high risk women, CA125 interpreted using a cut-off has been used in a number of 
older studies. Between 1993 and 2005, 888 women with a BRCA 1/2 mutation 
underwent annual screening with transvaginal ultrasound (TVS) and serum 
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CA125 interpreted using a cutoff. There were 10 incident cancer of which five 
were interval cancers which were diagnosed in women with a normal CA125 
screening result 3-10 months before diagnosis. Eight of the ten were stage III/IV 
(28). The strategy of annual TVS and serum CA125 with a cut-off lacked 
adequate sensitivity at 42%. In a cohort study of 1,100 women who were 
moderate-risk (4% to 10% lifetime risk) and high-risk (>10% lifetime risk) by 
Sterling (29) using a similar strategy of annual TVS and CA125 with a cut off, 
lead to the screen detection of ten of the 13 cancers, but majority were not 
detected at an early stage. In phase I of the UK Familial Ovarian Cancer Screening 
Study (UKFOCSS), between 2002 and 2008 3,563 women underwent annual 
screening with serum CA125 and TVS. CA125 cutoffs were 35U/mL for 
premenopausal and 30U/mL for postmenopausal women. Whilst the study 
showed encouraging sensitivity for the detection of OC/FT cancer within a year 
of the last annual screen, only 30.8% of the cancers detected by screening were 
Stage I/II. Advanced stage disease (>IIIC) was more likely in those that did not 
adhere to annual screening compared to those that did (85.7% versus 26.1%; 
p=0.009) (30).  
 
Serial monitoring is an essential part of screening.(31) Consequently efforts have 
been made to develop a more sophisticated approach to replace using absolute 
cut off levels for interpretation of CA125 levels. Analysis of data the pilot trial of 
ovarian cancer screening (32) of 22,000 volunteers who were followed up for a 
median of 8.6 years and included more than 50,000 serum CA125 measurements 
revealed that elevated CA125 levels in women without ovarian cancer were 
static or decreased with time, whereas levels associated with malignancy tended 
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to rise (33). These results were used to develop the Risk of Ovarian Cancer 
Algorithm. (ROCA), that uses age-specific incidence of ovarian cancer and 
comares the CA125 profile of the individual with known cases and controls (34) 
The risk increases the more the CA125 profile follows that of known ovarian 
cancer cases. Input of a woman’s age and dates and results of her serum CA125 
levels results in an estimated risk of the women having ovarian cancer, for 
example a ROC of 2% would indicate a risk of 1 in 50.  
 
Most high risk women wishing to access screening are pre- menopausal and 
interpretation of screening results is complicated by the presence of benign 
conditions (ovarian cysts, endometriosis) and changes in physiology (menstrual 
cycle) which both elevate CA125 levels and result in abnormalities on TVS and 
therefore a higher false positive rate. In a study by Sterling (29) of high risk 
women, annual screening with TVS and CA125 cutoff had a high false positive 
rate leading to unnecessary surgical intervention. Interpretation of CA125 using 
ROCA has been shown to improve specificity as women with static but elevated 
levels are being classified as low risk. The use of ROCA resulted in high specificity 
and positive predictive value in low risk population screening.(35) 
 
 
The ROCA also increases the sensitivity of CA125 compared with a single cut off 
value.  For a target specificity of 98%, the ROC calculation achieved a sensitivity 
of 86% for preclinical detection of ovarian cancer in the low risk population (36). 
The use of ROCA for general population screening in UK Collaborative Trial of 
Ovarian Cancer Screening (UKCTOCS) doubled the number of screen-detected 
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invasive epithelial ovarian cancer (iEOC) during incidence screening compared 
to a fixed cut off. ROCA detected 86% of the women with iEOC diagnosed within 
one year of screening, whereas using annual serum CA125 fixed cut-offs of >35, > 
30, and >22 U/mL would have identified only 41%, 48%, and 66%, respectively. 
(31) Other serial algorithms incorporating change in an individual’s CA125 over 
time as the cancer evolves has also been shown to have superior sensitivity and 
specificity in retrospective analysis of data from the US ovarian cancer screening 
trial. (37) (38). 
 
The ROCA is incorporated into a multimodal screening strategy. Women who 
undergo annual screening with CA125 that is interpreted using ROCA are 
subsequently triaged to routine screening if risk is normal, repeat testing with 
CA125 and /or TVS if risk is intermediate/ elevated and to clinical assessment if 
risk is severe. In the general/low risk postmenopausal population, UKCTOCS 
provided the first evidence that such a strategy may reduce deaths from ovarian 
cancer. (39). 
 
 
The ROCA was used in UKFOCSS Phase II (2007-2009) with more frequent 4-
monthly screening compared to the annual screening used in low-risk 
populations and previously adopted in high-risk trials . The preliminary results 
presented at the American Society of Clinical Oncology meeting in 2013 suggest 
that this strategy had high (67-100%) sensitivity for detection of ovarian and 
tubal cancers, with no interval cancers reported. However, only 42% of incident 
screen-detected OC/FT cancers were Stage I/II. This is in keeping with the 
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modelling studies from Brown & Palmer that suggest that for most of the occult 
period high grade serous ovarian cancers are less than 1cm in diameter and 
progress to stage III or IV when they are about 3cms. (40) There is a growing 
acceptance that while stage is important, tumour volume maybe a better 
prognostic indicator in invasive epithelial ovarian/tubal cancer. Most 
encouragingly in UKFOCSS Phase II, 92% of the incident cancers were completely 
cytoreduced compared to 62% on Phase I (p=0.16), implying detection of lower 
volume disease. While the results were encouraging, it is important to note that 
screening at present cannot be considered an effective alternative to risk-
reducing surgery(41). However in women who wish to delay or are not prepared 
to undergo RRSO a strategy of intensive surveillance as in UKFOCSS Phase II 
together with ongoing discussions about RRSO might be a safer option than 
symptom awareness alone. The study is expected to report its final results on the 
performance characteristics of multimodal screening using ROCA in high risk 
women in 2016.  
 
A similar screening strategy based on 3-monthly serum CA125 levels interpreted 
using ROCA was also assessed prospectively in the US screening trials in high-
risk women undertaken under the auspices of the Cancer Genetics Network (42) 
and Gynaecology Oncology Group (43). Sub group analysis of women who 
underwent RRSO at enrolment found significant association with abnormal 
CA125/TVS and detection of clinically occult neoplasm (44). Screening is 
complete in all of these trials with results expected later this year, and possible 
meta-analysis in the future. 
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HE4 a more recently described tumour marker is elevated in ovarian cancer but 
less frequently elevated in benign conditions such as endometriosis and studies 
suggsest it may help improve the performance of the screening strategy. (45). It 
is commercially available as Risk of Ovarian Malignancy Algorithm, ROMA, a test 
that combines HE4, CA125 II and menopausal status. Recent systematic review 
by Ferraro et al looking at the performance of HE4 and CA125 in identification of 
ovarian cancer in symptomatic women with suspected gynaecological disease 
concluded that HE4 is superior to CA125 using a cut off (46). More recently, the 
Copenhagen Index (CPH-I) which combines CA125, HE4 and age has been 
described and validated as an index that is easier to use as it does not include 
ultrasound findings and menopausal status(47) . Karlan et al studied the use of 
CA125 and HE4 in a screening study of women with increased risk of ovarian 
cancer defined by one of the following criteria 1) BRCA1/2 germline mutation, 2) 
fulfilling National Comprehensive Cancer Network (NCCN) high risk criteria and 
HPNCC or TP53 deleterious mutation 3) having 3 of 6 risk factors (<1 year of 
oral contraceptive use, null parity, no breastfeeding, no tubal ligation, Ashkenazi 
Jewish, >1 year of menopausal hormone therapy) or CA125, HE4, MMP7, or 
Mesothelin values exceeding the 95% population threshold. HE4 was either used 
as a first line test in conjunction with CA125 or as a second line screen after 
CA125. The results were interpreted using the parametric empirial Bayes (PEB)  
serial algorithm. The results suggested that in high-risk women HE4 may be 
useful as a confirmatory test in a multimodal strategy when CA125 alone was 
used as the primary screen. Additionally women were more likely to agree to a 
surgical consultation and procedure if recommended when rising CA125 was 
confirmed by a concurrent rising HE4. (48) 
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The modelling study (40) of occult serous ovarian cancer detected at RRSO in 
BRCA1 carriers suggest that to achieve 50% sensitivity in detecting tumours 
before they advance to stage III, an annual screening test would need to detect 
tumours that were 1.3cm in diameter at sizes 200 times smaller than those 
clinically apparent. To achieve 80% sensitivity, the tumours would have to be 
detected when 0.4cms in diameter.  This would require a truly ovarian cancer-
specific biomarker and/or alternative novel approaches. Mutations in cancer-
related genes TP53, EGFR, BRAF, and KRAS are among the most common early 
molecular genetic events in ovarian cancer. This opens up the possibility of 
detecting circulating tumour cells or tumour-derived DNA (ctDNA) in the blood 
(49) (50,51) or other novel samples such as endocervical. It has been shown that 
small amounts of tumour derived DNA containing these mutant alleles in cell-
free body fluids can be quantified with unprecedented sensitivity by new 
technologies such as BEAMing (52). BEAMing,  is a form of massive parallel 
sequencing that allows the transformation of a population of DNA fragments into 
a population of beads each  of which contains thousands of copies of the identical 
sequence. By using labels which distinguish beads containing DNA sequences of 
interest the incidence of these can be quantified.  In high grade serous 
carcinoma, where TP53 mutations are ubiquitous, (53) Forshew et al reported 
detecting high levels of ctDNA using tagged-amplicon deep sequencing (TAm-
Seq) for TP53 mutations in over 50% of patients with advanced high grade 
serous ovarian cancer. (54).  Tam-Seq will however need to achieve a more 
sensitive detection limit (<2% allele frequency) for identification of mutations in 
patients with early stage cancer. Further optimisations will hopefully allow high 
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throughput, low cost ‘liquid biopsy’ to allow detection of small tumours. Using 
liquid cytology cervical samples from 14 women with OC who had mutations, 
Kinde et al using massive parallel sequencing were were able to identify the 
expected tumour specific mutations using a panel of 12 genes. (55). Further 
encouraging results from a pilot study illustrates the feasibility of uterine cavity 
lavage to detect shed cancer cells and its ability to provide sufficient amounts of 
DNA in all patients. Using massive parallel sequencing and singleplex analysis 
mutations were identified in  80% (24/30) of women with ovarian cancer. (56) 
 
A separate but allied strategy explores use of autoantibodies (AAb) to tumor-
derived proteins. A study by Anderson et al. using sera of women diagnosed with 
ovarian cancer has identified autoantibodies to p53, PTPRA, and PTGFR as 
potential biomarkers for early detection of ovarian cancer.(57).  Yang has 
reported detecting TP53 AAb more commonly  in speciemens from women with  
ovarian cancer than control groups. Additionally  TP53  was found to be postivie 
prior to a rise in CA125 and also in women where the CA125 levels did not rise at 
all.(58) Another potentially minimally invasive approach is using saliva. Salivary 
transcriptomes have also been evaluated as possible OC markers. In a small 
study, Lee et al. showed that combination of five biomarkers (AGPAT1, B2M, 
BASP2, IER3 and ILI1) had a high sensitivity (85.7%) and specificity (91.4%) 
(59).  Further evaluation is required but the technique illustrates another 
potential minimally invasive future screening technique. 
 
The need to detect small serous ovarian cancers has shifted the focus of 
detection using transvaginal ultrasound from tumour blood flow using colour 
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Doppler on a macrovascular level to neovascularisation on a microvascular level, 
using contrast enhanced transvaginal ultrasound with microbubbles that are 
small enough to pass through capillaries the kinetics of blood flow.  Initial 
reports have indicated significant difference in enhancement patterns between 
benign and malignant ovarian tumours (60). Another novel way that small 
tumours and STIC lesions could be visualised is utilising autofluorescence 
patterns seen in tumours. Ex vivo data suggests that this is feasible and 
reproducible and is able to detect serous cancers with a high sensitivity (87.5 %) 
and specificity (92%) (61). 
 
Recommendations regarding OC screening in high risk women 
 
Currently screening of high-risk women is not recommended in the UK in the 
National Institute for Health and Care Excellence (NICE) guidelines.(62) and is 
therefore not available on the National Health Service (NHS). NICE does 
emphasise the importance of discussing the positive effects of reducing the risk 
of breast and ovarian cancer risk and the negative impact of surgically induced 
menopause. The NCCN primary recommendation for USA is for RRSO in women 
with BRCA1, BRCA2 and Lynch syndrome, with insufficient evidence for 
intervention in those with BARD1, BRIP1, PALB2, RAD51C and RAD51D 
mutations. In women who have not undergone RRSO, TVS starting age 30-35 and 
serum CA125 levels may also be considered at the clinician’s discretion. NCCN 
guidelines clearly state that these screening procedures have not been shown to 
have sufficient specificity or sensitivity and current research does not provide 
evidence that they are a reasonable alternative to RRSO. It is worth noting that 
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these guidelines may be revised in due course to incoporate the results of 
multimodal screening in UKFOCSS Phase II and UKCTOCS (39). 
 
Ocassionally CA125 is used for surveillance of BRCA women post RRSO due to 
the ssmall residual risk of primary peritoneal cancer. There is little evidence to 
support this. A recent study found that there was no significant difference in 
preoperative CA125 levels between BRCA1, BRCA 2 and non carriers. Post RRSO 
there was a significant reduction in CA125 levels in 48 BRCA1 women (p=0.04) 
but no significant different in 40 BRCA2 women (p=0.5). Based on the finding of 
only one case of post-operative peritoneal cancer in 220 carriers undergoing 
RRSO,, detected in an asymptomatic women with a raised annual CA125, the 
authors suggest that serum CA125 monitoring should be discontinued following 
RRSO. (63) 
 
Symptoms awareness 
 
Studies have shown that 95% of women with ovarian cancer report symptoms 
prior to diagnosis (64). Development of a symptom index that includes 
frequency and severity was reported to perform similarly to CA125 to detecting 
any stage of disease in a case control study  that incorporated women from an 
ovarian cancer early detection study (65). This has led organisations such as the 
NICE to issue recommendations that further investigations should be initiated if 
a woman has persistent abdominal distension/bloating, early satiety, loss of 
appetite, pelvic/abdominal pain and increased urinary urgency/frequency. (66). 
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Unfortunately symptoms associated with ovarian cancer can be non specific and 
are commonly found in women who do not have ovarian cancer (67). 
 
The DOvE pilot study found that assessment of symptomatic women via a fast 
track symptom clinic led to a lower tumour burden compared to those diagnosed 
via the standard referral route to the gynaecological oncological clinic in same 
hospital. However this was not asscoaited with an increase in early stage 
diagnosis. (68). Although the study design has been questioned (69) these 
findings emphasise the importance of assessing women as soon as symptoms 
occur.  Thus it is important that women at high risk of ovarian cancer are 
educated about symptom awareness and pathways are set up for rapid referral if 
key symptoms develop. Given the international variation in the perceived 
barriers to presenting with symptoms, (70) it is important to pre-empt and 
tackle any concerns women may have. 
 
 
Endometrial Cancer screening 
Lynch syndrome (previously referred to as hereditary nonpolyposis colorectal 
cancer /HNPCC) is an autosomal dominant disorder that is characterized by 
predisposition to early onset colorectal cancer and cancers of the endometrium, 
small intestine, ovary, hepatobiliary system, kidney, and ureter (71). It is caused 
by an inherited mutation in one of the following mismatch repair (MMR) genes: 
MSH2, MLH1, PMS1, PMS2, and MSH6.(72)  Individuals are diagnosed according 
to the Amsterdam II or the Bethesda criteria(72)(73). Endometrial cancer is the 
most frequent extra colonic cancer in these women and risk estimates may 
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exceed those of colorectal cancer (74)(75).  The exact lifetime risk varies with 
the gene mutation. Mutations in MLH1, MSH2, MHS6 and PMS2 confer a risk 
ranging from 15-54% compared to a general population risk of <2% (6)(76) 
Endometrial cancers in Lynch syndrome differ from sporadic endometrial 
carcinomas. They are more likely to be poorly differentiated, have 
lymphatic/vascular invasion and be diagnosed at an advanced stage (77). 
Cowden syndrome is an autosomal dominant syndrome that is characterised by 
hamartomatous tumors in multiple organ systems and it too is associated with 
an increased risk of endometrial cancer (78). Lifetime risk of developing 
endometrial cancer range between 10-28% (79). However, as the prevalence of 
Cowden’s syndrome is only 1 in 200,000, there are no uniform recommendations 
for risk management of endometrial cancer (79). 
 
Surveillance for women at risk of endometrial cancer is aimed at detection of 
atypical endometrial hyperplasia (AEH) or endometrial cancer at an early stage. 
It is based on detecting increased endometrial thickness (ET) on transvaginal 
ultrasound. While ET cut-offs have be defined in postmenopausal women,  in 
premenopausal women ET can be difficult to interpret as it varies through the 
menstrual cycle. Hence in LS annual or biennial pelvic ultrasound is not a very 
effective method to detect early endometrial carcinoma. In 269 Lynch Syndrome 
women during  825.7 women years of screening using transvaginal ultrasound, 
two cases of endometrial carcinoma were reported but both were not detected 
by screening. (80). Another study using annual TVS, reported on 41 women 
totalling 197 women years of screening. While three cases of AEH were detected, 
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one woman presented with an interval endometrial cancer detected as a result of 
clinical symptoms.(81). 
 
This has led to the use of endometrial sampling in addition to TVS in LS. In a 
Finnish study of 175 women (759 screen years) who underwent screening using 
TVS and intrauterine biopsy, endometrial cancer occurred in 14 women, 11 of 
whom were diagnosed by surveliance ( 8 by uterine biopsy, 4 by TVS . 
Intrauterine biopsy detected 14 additional women with premalignant 
hyperplasia. The authors concluded that surveillance with biopsy was more 
effective. (82). Gerritzen et al also found significantly more AEH and endometrial 
cancers in women using microcurretage or hysteroscopy and curettage 
combined with annual TVS compared to screening using by TVS alone (83). 
However, this was not confirmed in a separate study by Helder-Woolderink et al, 
who found that the addition of endometrial sampling using Pipelle to annual TVS 
had no additional value in  detection of endometrial lesions (84). However, the 
accuracy of endometrial sampling depends on the method used. Pipelle sampling 
can have an inadequate tissue yield and failure rate of approximately 10% (85).  
In contrast to endometrial biopsy, hysteroscopy has a high sentivity for the 
detection of hyperplasia or cancer with some studies reporting this to be 
100%.(86) A systematic review undertaken in 2011 concluded that detection of 
endometrial cancer or hyperplasia in asymptomatic women belonging to LS 
families is improved by adding routine endometrial sampling along with 
transvaginal ultrasound for surveillance visits.(87). More recently out- patient 
hysteroscopy and endometrial sampling (OHES) was compared to TVS alone in 
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41 LS women who had both annually. OHES had similar specificity of 89.8 % (CI 
79.2, 96.2 %) as TVS, but higher positive likelihood ratio 9.8 (CI 4.6, 21) and 
lower negative likelhood ratio  (zero) compared to. These results suggest that 
OHES is an acceptable screening method with a high diagnostic accuracy for 
endometrial cancer and atypical endometrial hyperplasia (88).  
 
A survey of women who underwent screening with regards to pain or discomfort 
associated with the procedures revealed that TVS was associated with less 
discomfort than hysteroscopy or Pipelle biopsy and that the majority of women 
would choose TVS if only a single test was required. The survey also found that 
there was no significant difference between the pain scores for hysteroscopy and 
Pipelle biopsy (89). A more recent prospective study of women undergoing 
combined colon and endometrial screening under conscious sedation reported 
high levels of satisfaction and more convenience in the combined procedure. In 
this patient-centred approach women reported significantly lower levels of pain 
compared with an office based procedure, even when accounting for parity (90). 
 
A potential future screening strategy could focus on the detection of micro-
satellite instability (MSI), which is found in more than 90% of endometrial 
cancers developed in Lynch syndrome women. Bats et al report encouraging 
sensitivity and feasibility of MSI detection in uterine cavity washings in a case 
series of 10 women with Lynch syndrome undergoing a hysterectomy for benign 
reasons, risk reduction and treatment of endometrial cancer (91). 
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A decision analytic model comparing annual  screening (ultrasonography, 
endometrial biopsy, CA 125) and hysterectomy with bilateral salpingo-
oophorectomy at age 30 years found that surgery in women with Lynch 
Syndrome led to the longest life expectancy (92). However, there are costs 
associated with both screening and preventative surgery. In a hypothetical 
cohort of women with Lynch syndrome, Kwon et al compared the cost of risk 
reducing surgery at 30 years, 40 years, annual screening with endometrial 
biopsy, transvaginal ultrasound, and CA125 from 30 years, annual screening 
from 30 years until risk reducing surgery at age 40 years (combined strategy) or 
no prevention. The combined strategy was found to be the most effective 
gynaecological cancer prevention strategy, but the incremental benefit over 
prophylactic surgery alone was attained at substantial cost (93). When 
prophylactic hysterectomy with bilateral salpingo-oophorectomy at age 30 was 
compared to annual gynaecological screening, risk-reducing surgery carried both 
the lowest costs and highest QALYs score. However the cost effectiveness of this 
surgery diminishes with increasing age. (94). A mixed methods study of 24 LS 
women exploring  the impact of surgery suggested that while it does not lead to 
significant psychological distress,  women reported feeling underprepared for 
menopausal symptoms. (95) 
 
Current guidelines for management of gynaecological cancer risk in LS are a 
result of consensus, based on the limited reported studies.  The Mallorca group 
which consist of a panel of European experts recommend surveillance of the 
endometrium by gynaecogical examination, TVS and aspiration biopsy starting 
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from the age of 35–40 years (96). However they suggest that given the current 
ack of evidence of benefit, it is best offered within a clinical trial setting. The 
2015 American College of Gastroenterology guidelines recommend annual 
screening using endometrial biopsy and transvaginal ultrasound from 30 to 35 
years with surgery offered to LS women who have finished child bearing, 
optimally at age 40–45 years. (97)The American Society of Clinical Oncology and 
European Society for Medical Oncology have similar guidelines which include 
annual screening with TVS and aspiration biopsy with prophylactic 
gynecological surgery an option from age 35, after childbearing is 
completed.(98) 
  
Psychological impact of screening 
 
It is essential to recognise the psychological aspect of screening high-risk 
women. Premenopausal women perceive their ovarian cancer risk to be higher, 
report greater disease risk-related anxiety, and are more likely to have false-
positive screening results than postmenopausal women (99). Brain et al found 
that women, in UKFOCCS trial, who are recalled for an abnormal result, may 
experience transient cancer-specific distress, which may prompt reconsideration 
of risk management options. However frequent 4 monthly ovarian screening in 
the high risk women did not cause sustained psychological harm or have a 
significant impact on general anxiety and depression (100). In women who 
participated in UKFOCSS, experience of previous screening, cancer specific 
distress and a belief in aging as a cause of OC were significantly associated with 
withdrawal from screening and opting for surgery (101). 
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Conclusions 
 
Surgery is recommended as the definitive option to reduce risk in women at high 
risk of ovarian cancer and to a lesser extent in women at increased risk of 
endometrial cancer. However, the fear of surgery and the sid effects of 
premature menopause often result in some women seeking screening in order to 
either postpone or avoid surgery. However screening in this population of 
women who are mainly premenopausal has additional challenges when 
compared to the general postmenopausal population. Annual screening is 
ineffective and strategies that are being investigated are based on 3-4 monthly 
screening with serial CA125 levels interpreted using the ROCA together with 
second line TVS. Detailed results of both the UK and US studies are expected in 
2016. With increasing understanding of the natural history, a number of novel 
ovarian cancer screening strategies are being explored.  In Lynch Syndrome 
women, endometrial cancer screening is offered from 30-35 years and includes 
annual TVS and endometrial biopsy, with increasing use of outpatient 
hysteroscopy.   
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